Latest press releases
- David Brennan to retire as AstraZeneca’s Chief Executive Officer
- 26 April 2012
- AstraZeneca PLC First quarter results 2012
- 26 April 2012
- AstraZeneca and The Medicines Company announce global collaboration in acute ischaemic heart disease
- 25 April 2012
- AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash) including lead product lesinurad in Phase III development for gout
- 23 April 2012
- FORXIGA (dapagliflozin) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes
- 20 April 2012
- AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio
- 2 April 2012
- US DISTRICT COURT FINDS SEROQUEL XR® FORMULATION PATENT VALID AND INFRINGED
- 30 March 2012
- US court denies preliminary injunction application against the FDA and dismisses AstraZeneca’s lawsuit without prejudice
- 26 March 2012
- UK court finds SEROQUEL XR® formulation patent invalid
- 22 March 2012
Annual information update
This update relates to information that has been published or made available to the public between 8 April 2011 and 10 April 2012.
Annual information update 2012 (PDF 73kb)Currency guidance
Financial results
First quarter results 2012 announced Thursday, 26 April 2012.
Annual Report 2011
Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and make a meaningful difference for patients worldwide.